GE HealthCare Technologies Inc. (GEHC) 2023 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good day, and welcome to GE HealthCare's Fourth Quarter 2023 Earnings Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Carolynne Borders, Chief Investor Relations Officer. Please go ahead.

    各位好,歡迎參加 GE HealthCare 2023 年第四季財報電話會議。(接線員指示)請注意,今天的會議將被錄音。現在我想把會議交給今天的講者——投資人關係長 Carolynne Borders。請開始。

  • Carolynne Borders - Chief IR Officer

    Carolynne Borders - Chief IR Officer

  • Thank you. Good morning, and welcome to GE HealthCare's Fourth Quarter 2023 Earnings Call. I'm joined by our President and CEO, Peter Arduini; and our Vice President and CFO, Jay Saccaro.

    謝謝。各位早安,歡迎參加 GE HealthCare 2023 年第四季財報電話會議。我與我們的總裁暨執行長 Peter Arduini,以及副總裁暨財務長 Jay Saccaro 一同出席。

  • Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures can be found in today's press release and in the presentation slides available on our website.

    我們在電話會議中的發言將同時包含 GAAP 與非 GAAP 財務結果。GAAP 與非 GAAP 指標之間的調節表可在今日新聞稿以及我們網站上的簡報投影片中查閱。

  • During this call, we'll make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties.

    在本次電話會議中,我們將就公司表現發表前瞻性陳述。這些陳述係基於我們目前對情勢的看法。如同我們向 SEC 提交的文件所述,由於風險與不確定性,實際結果可能與前述陳述存在重大差異。

  • And with that, I'll hand the call over to Peter.

    那麼,我把電話交給 Peter。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Thanks, Carolynne. Let me start by providing a few highlights from a successful first year as a public company. I'm proud of how our teams executed to deliver robust financial results with performance that all met or exceeded guidance. In fact, our execution throughout the year allowed us to raise guidance twice.

    謝謝,Carolynne。讓我先分享我們作為上市公司成功第一年的幾項重點。我為團隊的執行力感到自豪,我們交出了強勁的財務成果,表現皆達到或超越指引。事實上,我們全年持續的執行力讓我們兩度上調指引。

  • We've continued to increase our R&D investment, launching over 40 new innovations tied to our care pathway and digital strategy. As a result of our investments, we estimate that we've gained global market share in equipment in 2023. And once again, we topped the FDA's list of AI-enabled device authorizations with 58, more than any other medtech company.

    我們持續提高研發投資,推出超過 40 項與我們照護流程與數位策略相關的新創新。受惠於這些投資,我們估計 2023 年在設備方面取得了全球市占率提升。此外,我們再次以 58 項 AI 賦能醫療器材核准數量名列 FDA 榜首,超過任何其他醫療科技公司。

  • Backlog remains robust led by an improved capital equipment landscape. And we significantly strengthened our balance sheet as we paid down $1 billion in debt since the beginning of the fourth quarter.

    在資本設備環境改善的帶動下,訂單積壓(backlog)仍然強勁。同時,自第四季初以來我們已償還 10 億美元債務,顯著強化了資產負債表。

  • Our financial flexibility enables us to drive both organic and inorganic investment such as the Caption Health and IMACTIS acquisitions completed in 2023. More recently, we announced our plans to acquire MIM Software, which I'll discuss in greater detail later in the call. We continue to build our position as a trusted partner, and here are a few highlights from throughout the year.

    我們的財務彈性使我們能推動有機與無機投資,例如 2023 年完成的 Caption Health 與 IMACTIS 收購。更近期,我們宣布計畫收購 MIM Software,我稍後會在電話會議中更詳細說明。我們持續鞏固作為值得信賴合作夥伴的地位,以下是全年幾項重點。

  • On the commercial side, we secured multiyear enterprise deals globally with contract values totaling approximately $2.5 billion in 2023, fueling our growth. We also expanded our 4-year relationship with the University of Wisconsin-Madison by entering a 10-year strategic collaboration that goes beyond medical imaging to new frontiers and digital technologies and disease-focused solutions.

    在商務面,我們於 2023 年在全球取得多年度企業級合約,合約價值合計約 25 億美元,推動我們的成長。我們也透過簽訂為期 10 年的策略合作,擴大與威斯康辛大學麥迪遜分校長達 4 年的合作關係;該合作不僅涵蓋醫學影像,也延伸至新領域、數位技術與以疾病為導向的解決方案。

  • Separately, the Bill & Melinda Gates Foundation and BARDA, a division within the U.S. Department of Health and Services, are funding programs totaling over $80 million that will allow us to develop new AI applications for ultrasound, benefit patients in low- and middle-income countries and patients with lung pathologies and traumatic injuries.

    另外,比爾與梅琳達・蓋茲基金會以及 BARDA(美國衛生與公共服務部轄下的一個部門)正資助總額超過 8,000 萬美元的計畫,使我們能為超音波開發新的 AI 應用,造福低與中等收入國家的病患,以及患有肺部病理與外傷性傷害的病患。

  • We also announced a collaboration with Novo Nordisk to advance the clinical and product development of peripheral-focused ultrasound.

    我們也宣布與 Novo Nordisk 合作,以推進以周邊為重點的超音波之臨床與產品開發。

  • We've assembled a strong world-class leadership team. Jay Saccaro joined us last year and has had an immediate impact. He's had the opportunity to assess our organizational needs, forecasting models, financial systems and processes and is adding significant strategic and operational value.

    我們已建立一支強大、世界級的領導團隊。Jay Saccaro 去年加入我們並立即產生影響。他有機會評估我們的組織需求、預測模型、財務系統與流程,並帶來顯著的策略與營運價值。

  • Similarly, Taha joined us as Chief Technology Officer more than a year ago. And he's been charting our digital future and strategy while building a high-performing team of top healthcare technology experts.

    同樣地,Taha 於一年多前加入我們擔任技術長。他正規劃我們的數位未來與策略,同時打造一支由頂尖醫療照護科技專家組成的高績效團隊。

  • In 2023, we published our inaugural sustainability report, highlighting our progress and commitment to corporate responsibility and risk management. Lastly, we introduced 2024 guidance today, which Jay will discuss in greater detail.

    在 2023 年,我們發布首份永續報告,突顯我們在企業責任與風險管理方面的進展與承諾。最後,我們今天也提出 2024 年指引,Jay 將進一步詳細說明。

  • Our outlook reflects an improved capital equipment landscape. It also reflects continued strength on top of 2 consecutive years of high single-digit organic sales growth.

    我們的展望反映資本設備環境的改善,也反映在連續兩年高個位數有機銷售成長之上的持續強勁表現。

  • Similar to last quarter, we conducted a survey of a broad set of U.S. customers, which supports our forecast for 2024. Our latest survey showed improved financial optimism and capital budget outlook versus the last survey in October. Global procedures remain strong, which we believe all of this points to a constructive setup for the year.

    與上季相同,我們對廣泛的美國客戶進行調查,以支持我們對 2024 年的預測。最新調查顯示,相較於 10 月的上一份調查,財務樂觀程度與資本預算展望均有所改善。全球醫療處置量仍然強勁,我們認為這些因素都指向今年具建設性的布局。

  • Now I'll pass the call on to Jay to take us through the financials and our business performance. And I'll conclude the call with a discussion around our R&D commitments and the innovation we're delivering for customers. Jay?

    現在我把電話交給 Jay,帶大家回顧財務表現與業務表現。我將在最後就我們的研發承諾以及為客戶帶來的創新做總結。Jay?

  • James K. Saccaro - VP & CFO

    James K. Saccaro - VP & CFO

  • Thanks, Pete. Let's start with our financial performance on Slide 4. For the fourth quarter of 2023, revenues of $5.2 billion increased 5% year-over-year and grew 5% organically. This was driven by sales in Pharmaceutical Diagnostics, Imaging and Patient Care Solutions. Recall that this 5% organic growth was on top of the 13% we delivered in the fourth quarter of 2022, which benefited from easing supply chain.

    謝謝,Pete。先從第 4 張投影片的財務表現開始。2023 年第四季,營收 52 億美元,年增 5%,有機成長亦為 5%。成長動能來自藥物診斷(Pharmaceutical Diagnostics)、影像(Imaging)與病患照護解決方案(Patient Care Solutions)的銷售。請記得,這 5% 的有機成長是建立在 2022 年第四季 13% 成長的高基期之上,而 2022 年第四季受惠於供應鏈緩解。

  • Organic orders increased 3% year-over-year. Order dollars continue to outpace sales, leading to a total company book-to-bill of 1.05x, up sequentially from 1.03x due to healthy product orders, including equipment.

    有機訂單年增 3%。訂單金額持續快於銷售,使公司整體出貨比(book-to-bill)達 1.05 倍,較前一季的 1.03 倍上升,主要因產品訂單健康,包括設備訂單。

  • We exited the year with a record backlog of $19.1 billion, up $700 million sequentially. This performance gives us continued confidence in our expectations for 2024.

    我們在年底的訂單積壓創下 191 億美元新高,較前一季增加 7 億美元。這樣的表現讓我們對 2024 年的預期持續充滿信心。

  • Fourth quarter adjusted EBIT margin was 16.1%. Sequentially, margin improved 70 basis points, supported by seasonally higher volume while we expanded our investment in future innovation. Year-over-year, standalone adjusted EBIT margin was flat as benefits from productivity and price were offset primarily by investments.

    第四季調整後 EBIT 利潤率為 16.1%。按季來看,利潤率提升 70 個基點,受季節性較高的出貨量支持,同時我們也擴大對未來創新的投資。年對年來看,獨立口徑(standalone)的調整後 EBIT 利潤率持平,生產力與價格帶來的效益主要被投資所抵銷。

  • The lean methodology is at the foundation of our productivity, yielding strong performance in the fourth quarter with improvements in logistics, [sourcing] and services. Our teams came together to increase on-time delivery to our customers by 11% year-over-year with lean actions improving demand forecast accuracy, supplier planning and lead times. We also saw a past-due backlog efficiency with a greater than 50% improvement year-over-year in Imaging alone.

    精實方法(lean methodology)是我們生產力的基礎,第四季在物流、[採購] 與服務方面的改善帶來強勁表現。我們的團隊攜手合作,透過精實行動提升需求預測準確度、供應商規劃與交期,使準時交付率年增 11%。此外,僅在影像業務中,我們也看到逾期訂單積壓效率年對年改善超過 50%。

  • For the fourth quarter, we delivered adjusted EPS of $1.18, up 11% on a standalone basis. Free cash flow of $956 million was down slightly year-over-year. This was impacted by approximately $330 million of spin-related items such as interest and post-retirement benefit payments.

    第四季我們交出調整後 EPS 1.18 美元,以獨立口徑計年增 11%。自由現金流為 9.56 億美元,年對年略降。主要受到約 3.3 億美元分拆(spin)相關項目影響,例如利息與退休後福利支付。

  • Turning to our full year results on Slide 5. For 2023, revenues of $19.6 billion grew 8% organically versus last year. All of our regions and segments saw a positive revenue growth.

    接著看第 5 張投影片的全年結果。2023 年營收 196 億美元,較去年有機成長 8%。我們所有地區與事業部門的營收皆呈現正成長。

  • Also important to note, recurring revenue, which drives revenue predictability and higher margin, was greater than 45% of total revenues for the year. Organic orders grew 3% year-over-year, and book-to-bill was 1.03x.

    同樣重要的是,能提升營收可預測性並帶來較高利潤率的經常性收入(recurring revenue),全年占總營收超過 45%。有機訂單年增 3%,出貨比為 1.03 倍。

  • On a standalone basis, 2023 adjusted EBIT margin was up 60 basis points. Adjusted EPS of $3.93 exceeded our guidance and represented standalone growth of 16%.

    以獨立口徑計,2023 年調整後 EBIT 利潤率提升 60 個基點。調整後 EPS 為 3.93 美元,超越我們的指引,並代表獨立口徑 16% 的成長。

  • Free cash flow was more than $1.7 billion and translated into a strong conversion rate of 95%, which was ahead of our guidance for the year. This was driven by the solid progress we made in working capital associated with multiple initiatives focused on inventory and collections processes.

    自由現金流超過 17 億美元,換算為 95% 的強勁轉換率,高於我們全年指引。這主要來自我們在營運資金方面的扎實進展,與多項聚焦於存貨與收款流程的計畫相關。

  • On Slide 6, let's take a closer look at segment revenue performance for the year. For full year '23, we delivered strong year-over-year organic growth of 8% for revenues. This was led by PDx with 18% growth, PCS at 8% and Imaging at 7% driven by both volume and price.

    在第 6 張投影片,我們更深入看看全年各事業部門的營收表現。2023 全年,我們的營收年對年有機成長 8%,表現強勁。成長由 PDx 的 18% 增長領軍,PCS 成長 8%,影像成長 7%,動能同時來自出貨量與價格。

  • Ultrasound organic revenue increased 2%. Recall that in 2022, we had multiple quarters of strong Ultrasound results as supply chain constraints eased. I'd also note that all segments delivered positive price in the year, reflecting our continued pricing discipline.

    超音波(Ultrasound)有機營收成長 2%。請記得,2022 年因供應鏈限制緩解,超音波在多個季度都有強勁表現。我也要指出,所有事業部門在全年都實現正向價格,反映我們持續的定價紀律。

  • Looking ahead, we believe all of our segments are well positioned as we move into 2024 from both an innovation and operational perspective. I'll walk through more details on this for each segment shortly.

    展望未來,我們相信,從創新與營運兩個面向來看,隨著我們邁入 2024 年,我們所有業務部門都已具備良好定位。我稍後將針對各部門進一步說明更多細節。

  • Turning to the progress we made in 2023 on margin initiatives on Slide 7. As we move through the year, we drove sequential improvements in adjusted EBIT margin driven by volume, commercial execution and productivity.

    接著看投影片 7,說明我們在 2023 年於毛利率改善措施上的進展。隨著年度推進,我們在銷量、商業執行與生產力的帶動下,推動調整後 EBIT 利潤率逐季改善。

  • For the year, we increased adjusted gross margin by 120 basis points versus 2022 and delivered more than 3% in positive sales price for the year, ahead of our expectations. In 2024, we expect 1 to 2 percentage points of positive price as we deliver increasing value to our customers.

    全年而言,我們的調整後毛利率較 2022 年提升 120 個基點,並實現全年超過 3% 的正向售價貢獻,優於我們的預期。2024 年,我們預期將有 1 至 2 個百分點的正向價格貢獻,因為我們將持續為客戶提供更高價值。

  • We're also starting to see margin expansion from improving volumes and higher-margin NPIs, given our continued R&D investment. For the year, we invested more than $1 billion in R&D, equating to over 6% of sales, all while expanding margins. In 2024, we expect to be in the same range as a percent of sales or slightly higher, supporting our innovative (inaudible) pipeline.

    在我們持續投入研發的情況下,隨著銷量改善與較高毛利的新產品導入(NPI),我們也開始看到利潤率擴張。全年我們研發投入超過 10 億美元,相當於銷售額的 6% 以上,同時仍能擴大利潤率。2024 年,我們預期研發占銷售額比重將維持在相近區間或略高,以支持我們具創新性的(聽不清)產品管線。

  • Our productivity initiatives have also gained traction as logistics costs continue to improve, spot buys decrease and as we implemented, cost-efficient design changes. We have also experienced improved labor productivity driven by a greater proportion of remote fix and the application of digital tools.

    隨著物流成本持續改善、現貨採購減少,以及我們導入具成本效益的設計變更,我們的生產力提升措施也已逐步見效。我們也因遠端修復占比提高與數位工具的應用,而看到勞動生產力改善。

  • Relative to G&A, we're optimizing our spend by rightsizing our real estate footprint and IT infrastructure to generate additional efficiencies. We made solid progress in exiting TSAs in 2023 with nearly 280 completed through the end of 4Q. We're on track to exit the vast majority of the remaining TSAs in 2024, which gives us confidence in our G&A optimization plans, an important part of reaching medium-term margin goals.

    在 G&A 方面,我們透過縮減不動產使用面積與 IT 基礎設施規模來最佳化支出,以創造額外效率。2023 年我們在退出 TSA 方面取得扎實進展,截至第四季末已完成近 280 項。我們正按計畫於 2024 年退出絕大多數剩餘 TSA,這讓我們對 G&A 最佳化計畫更具信心,而這也是達成中期利潤率目標的重要一環。

  • Given our progress across the organization, we have solid visibility to deliver on our high teens to 20% adjusted EBIT margin target over the medium term.

    鑑於我們在全組織的進展,我們對於在中期達成調整後 EBIT 利潤率介於高十位數至 20% 的目標具有良好能見度。

  • Now I'll turn to our segments. As a reminder, in 2023, we incurred approximately $200 million of recurring standalone costs that impact our segment EBIT margin rates. We did not have these expenses in 2022. These costs were allocated based on revenue and equated to approximately 100 basis points of margin headwind for each segment.

    接下來我將說明各業務部門。提醒一下,2023 年我們發生約 2 億美元的經常性獨立營運成本,影響各部門的 EBIT 利潤率。2022 年並無這些費用。這些成本依營收分攤,約相當於各部門利潤率 100 個基點的不利因素。

  • Going forward, these costs will be in our run rate but serve as an opportunity to operate more efficiently in the future.

    展望未來,這些成本將納入我們的常態化費用水準,但也提供我們在未來以更高效率營運的機會。

  • Let's start with our Imaging segment on Slide 8, where we generated organic revenue growth of 4% year-over-year. This was driven by improved backlog conversion and price. Growth was up against fourth quarter sales that experienced a strong double-digit increase in 2022.

    先從投影片 8 的影像(Imaging)部門開始,我們的有機營收年增 4%。這主要由在手訂單轉換改善與價格所帶動。成長基期則是 2022 年第四季銷售額曾出現強勁的雙位數增幅。

  • Segment EBIT margin was up 10 basis points year-over-year as we made progress on enhancing gross margin. Imaging equipment growth outpaced service growth in the quarter and for the year, which impacted margin mix as we build our installed base with future service growth opportunity.

    部門 EBIT 利潤率年增 10 個基點,反映我們在提升毛利率方面的進展。本季與全年影像設備成長均快於服務成長,影響了利潤率組合,因為我們正在擴大裝機基礎,以創造未來服務成長機會。

  • We saw strong progress in our product platforming initiatives across several modalities, including CT and MR. Customer with demand for our Imaging product remains healthy, and our growing backlog is driven by new product introductions.

    我們在多項產品平台化計畫上取得顯著進展,涵蓋多種影像模態,包括 CT 與 MR。客戶對我們影像產品的需求仍然健康,而我們持續成長的在手訂單主要由新產品導入所驅動。

  • Turning to Ultrasound on Slide 9. Organic revenue was down 2% year-over-year due to the impact of lower volume tied to a challenging comparison for the same period last year. We continue to have a positive outlook for this segment as we enter 2024.

    接著看投影片 9 的超音波(Ultrasound)。由於銷量下降,且去年同期比較基期具挑戰性,有機營收年減 2%。隨著我們邁入 2024 年,我們對此部門仍維持正向展望。

  • Segment EBIT margin declined year-over-year due to investments such as the Caption Health artificial intelligence integration. This year-over-year margin decline was partially mitigated by cost productivity as we drove standardization and commonality across our platforms.

    部門 EBIT 利潤率年減,主要因 Caption Health 人工智慧整合等投資所致。這項年減部分被成本生產力所抵銷,因為我們推動平台間的標準化與共通化。

  • As we exited the year, we saw opportunities for Ultrasound equipment based on a combination of our commercial efforts and improving market conditions. With recent customer commitments and interest in new products enhanced by AI technology, we're well positioned as we enter 2024.

    在年度結束時,基於我們的商業推進與市場狀況改善的綜合作用,我們看到了超音波設備的機會。隨著近期客戶承諾,以及對導入 AI 技術強化之新產品的興趣提升,我們在邁入 2024 年時具備良好定位。

  • Moving to Patient Care Solutions on Slide 10. Organic revenue was up 4% driven by progress on price and operational process improvements. Revenue increased as we fulfill more backlog in addition to contribution from NPIs.

    接著看投影片 10 的病患照護解決方案(Patient Care Solutions)。有機營收年增 4%,主要由價格進展與營運流程改善所帶動。隨著我們交付更多在手訂單,並加上新產品導入(NPI)的貢獻,營收有所增加。

  • Similar to Imaging, recall that sales growth in the fourth quarter last year increased double digits due to an easing supply chain environment. PCS margin decreased 320 basis points compared to last year driven by investments and onetime favorability that we experienced in the prior year.

    與影像部門類似,請記得去年第四季因供應鏈環境緩解,銷售成長達雙位數。PCS 利潤率較去年下降 320 個基點,主要由投資增加以及去年出現的一次性有利因素所致。

  • During the quarter, the team delivered on improved supplier lead times and lower inventory. As we look ahead, we're excited about recent product launches that should contribute to future growth.

    本季團隊在供應商交期改善與庫存降低方面達成成果。展望未來,我們對近期產品上市感到振奮,這些產品應可為未來成長帶來貢獻。

  • Finally, moving to Pharmaceutical Diagnostics on Slide 11. We have another solid quarter, generating 23% year-over-year organic growth associated with an easier year-over-year comparison and pricing.

    最後看投影片 11 的藥品診斷(Pharmaceutical Diagnostics)。我們再度交出穩健的一季,受惠於較容易的年對年比較基期與定價因素,有機成長年增 23%。

  • Segment EBIT margin of 24.4% improved 140 basis points year-over-year driven by price, volume and productivity actions. We're encouraged by the continuing strength of global imaging procedures, which drives the need for imaging agents.

    部門 EBIT 利潤率為 24.4%,年增 140 個基點,主要由價格、銷量與生產力措施所帶動。全球影像檢查量持續強勁,推動對顯影劑的需求,這讓我們備受鼓舞。

  • We are executing on our innovation strategy through investments in our pipeline across care areas, including the in-licensing of FAPI assets, which we believe will play a key role in targeting this protein to detect certain types of cancer. This is an area of significant potential for the nuclear medicine and oncology communities.

    我們透過在各照護領域的產品管線投資來執行創新策略,包括引進授權(in-licensing)FAPI 資產;我們相信這將在鎖定該蛋白以偵測特定癌症類型方面扮演關鍵角色。這對核醫與腫瘤領域具有顯著的潛力。

  • Turning to Slide 12, I'll walk through our cash flow performance. We exited the year with an improved financial profile, including a stronger balance sheet and enhanced financial flexibility to support our future growth.

    接著看投影片 12,我將說明我們的現金流表現。我們在年底時展現更佳的財務概況,包括更強健的資產負債表,以及更高的財務彈性以支持未來成長。

  • We generated free cash flow of $956 million during the fourth quarter, down $31 million year-over-year with standalone cash outflows.

    第四季我們創造自由現金流 9.56 億美元,年減 3,100 萬美元,主要因獨立營運相關的現金流出。

  • Inventory turns improved in the quarter, the highest they have been since the beginning of 2021. This is the result of our lean supply chain actions. We saw operational improvements, including lead time reductions and greater inventory turns in all segments. Our aged inventory balance decreased, and we have stronger input controls in place, including safety stock reduction and optimized stock planning.

    本季庫存周轉率改善,為自 2021 年初以來最高,這是我們精實供應鏈措施的成果。我們在所有部門都看到營運改善,包括交期縮短與庫存周轉提升。我們的逾齡庫存餘額下降,且已建立更強的投入控制措施,包括降低安全庫存與最佳化備貨規劃。

  • In addition, our collections improved as a result of our focused daily management system.

    此外,在我們聚焦的日常管理系統帶動下,收款表現也有所改善。

  • For the year, we delivered strong free cash flow of over $1.7 billion. This equates to 95% free cash flow conversion. We also strengthened our balance sheet by paying down $1 billion of debt since the start of the fourth quarter. With a strong balance sheet and a balanced capital allocation strategy, we'll continue to focus on organic and inorganic investment, deleveraging and paying a dividend.

    全年而言,我們交出超過 17 億美元的強勁自由現金流,相當於 95% 的自由現金流轉換率。自第四季初以來,我們也透過償還 10 億美元債務來強化資產負債表。在強健的資產負債表與均衡的資本配置策略下,我們將持續聚焦於有機與無機投資、去槓桿,以及發放股利。

  • Now let's turn to our outlook on Slide 13. For 2024, we expect organic revenue growth to be approximately 4%. This compares to strong growth of 8% in '23 that was driven by easing supply chains and price gains. I would note that we expect a foreign exchange headwind to revenue of less than 1% in 2024.

    現在看投影片 13 的展望。2024 年,我們預期有機營收成長約 4%。相較之下,2023 年在供應鏈緩解與價格提升帶動下,成長強勁達 8%。我也要指出,我們預期 2024 年外匯對營收的不利影響將低於 1%。

  • We expect full year adjusted EBIT margin to be in the range of 15.6% to 15.9%, representing expansion of 50 to 80 basis points, given the progress we're making with volume, commercial execution and optimization. We assume an adjusted effective tax rate in the range of 23% to 25%. The [Pillar 2] global minimum tax is not anticipated to have a significant impact on our tax expense in 2024.

    我們預期全年調整後 EBIT 利潤率將介於 15.6% 至 15.9%,代表擴張 50 至 80 個基點,反映我們在銷量、商業執行與最佳化方面的進展。我們假設調整後有效稅率介於 23% 至 25%。[Pillar 2] 全球最低稅負預期不會在 2024 年對我們的稅負費用造成重大影響。

  • On adjusted EPS, we expect to deliver between $4.20 and $4.35 for the full year, representing growth in the range of 7% to 11% versus 2023. Lastly, we expect to deliver free cash flow of approximately $1.8 billion for the full year.

    在調整後 EPS 方面,我們預期全年將達到 4.20 至 4.35 美元,較 2023 年成長約 7% 至 11%。最後,我們預期全年自由現金流約為 18 億美元。

  • While we don't give quarterly guidance, it's important to note that given the seasonal nature of our business, the fourth quarter is typically the strongest period for orders, sales dollars and adjusted EBIT margin. We expect year-over-year organic revenue growth and adjusted EBIT margin in the first quarter to be the lowest of the year. Also remember that organic sales growth in the first half of 2023 was very strong at 11%. As a result, organic revenue growth is expected to be stronger in the second half of the year versus the first half in 2024.

    雖然我們不提供季度指引,但需要注意的是,基於我們業務的季節性特徵,第四季通常是訂單、銷售金額與調整後 EBIT 利潤率最強的期間。我們預期第一季的年對年有機營收成長與調整後 EBIT 利潤率將是全年最低。同時也請記得,2023 年上半年有機銷售成長非常強勁,達 11%。因此,2024 年的有機營收成長預期在下半年將較上半年更強。

  • To wrap up, we're entering 2024 from a position of strength as we executed well in 2023. Our solid backlog, order intake and adjusted EBIT margin progress gives us confidence in our ability to deliver on our guidance for 2024.

    總結來說,我們在 2023 年執行表現良好,因此以強勁態勢邁入 2024 年。我們穩健的在手訂單、接單表現以及調整後 EBIT 利潤率的改善,讓我們對於達成 2024 年財測指引的能力充滿信心。

  • Now I'll hand the call back over to Pete.

    現在我把電話交回給 Pete。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Thanks, Jay. Through an emphasis on R&D, we continue to innovate across our 4 segments. Our new product vitality index, which measures new products contributing to orders in the year, was healthy at 26%. We launched more than 40 new innovations in 2023 as I noted before, many of which are AI and digitally enabled, bringing more opportunity to increase gross margin with these enhanced capabilities.

    謝謝你,Jay。透過強調研發(R&D),我們持續在四大事業部門推動創新。我們的新產品活力指數(衡量當年度對訂單有貢獻的新產品)維持健康水準,達 26%。如我先前提到的,我們在 2023 年推出超過 40 項新創新,其中許多具備 AI 與數位賦能,藉由這些強化能力帶來更多提升毛利率的機會。

  • Earlier, I mentioned our plans to acquire MIM Software, a leader in AI-enabled image analysis and workflow tools across multiple care areas. Once integrated post close, MIM is expected to drive accretive top line growth. And we expect the transaction to be neutral to adjusted EBIT in year 1 and accretive thereafter.

    先前我提到我們計畫收購 MIM Software,該公司是多個照護領域中 AI 賦能影像分析與工作流程工具的領導者。交易完成並整合後,預期 MIM 將帶來具增益性的營收成長。我們也預期該交易在第 1 年對調整後 EBIT 為中性,之後則具增益性。

  • One of the dilemmas our customers face is integrating the variety of multi-vendor AI applications into their workflows. Our new App Orchestrator is a solution that simplifies the AI selection, integration and workflow process for healthcare professionals. By providing easy access to prevalidated apps, we're helping reduce the pressure that often comes with the overhead of evaluating, acquiring and implementing solutions from many companies.

    客戶面臨的其中一個難題,是如何將多家供應商的各式 AI 應用整合進其工作流程。我們全新的 App Orchestrator 是一項解決方案,可為醫療專業人員簡化 AI 的選擇、整合與工作流程。透過提供可輕鬆存取的預先驗證應用程式,我們正協助降低客戶在評估、採購並導入多家公司解決方案時常見的管理負擔與壓力。

  • We're in the process of developing the subscription-based application for the cloud. Our high-growth, high-margin AI solutions are designed to increase productivity, efficiency and diagnostic confidence.

    我們正在開發雲端的訂閱制應用程式。我們高成長、高毛利的 AI 解決方案旨在提升生產力、效率與診斷信心。

  • Customers have the option to purchase new AI-equipped devices or as an upgrade to existing equipment. We're actively pursuing AI across our product portfolio with a focused effort to expedite product development in 2024.

    客戶可選擇購買配備 AI 的新設備,或將 AI 作為既有設備的升級。我們正積極在產品組合中推進 AI,並在 2024 年聚焦加速產品開發。

  • Moving to molecular imaging on Slide 15 and the role of MIM Software to enhance our precision care strategy. For starters, our unique portfolio of PET/MR, PET/CT and multi-head SPECT/CT, radio tracers and digital offers providers a comprehensive solution to deliver on this growing field of diagnostics and therapeutics.

    接著看第 15 頁的分子影像,以及 MIM Software 在強化我們精準照護策略中的角色。首先,我們獨特的 PET/MR、PET/CT 與多探頭 SPECT/CT 產品組合、放射性示蹤劑與數位化方案,為醫療服務提供者提供一套完整解決方案,以因應這個快速成長的診斷與治療領域。

  • As novel therapies become more widely available, our tracers play an increasingly important role, putting us at the center of this transformation of care that will help enable better patient outcomes across many care pathways as functional imaging expands. This chart illustrates the diversity of our pharmaceutical portfolio, both existing and in the pipeline, and the diseases that each one uniquely targets.

    隨著新型療法更廣泛可得,我們的示蹤劑扮演愈來愈重要的角色,使我們站在這場照護轉型的核心;隨著功能性影像的擴展,這將有助於在多種照護路徑中帶來更佳的病患結果。此圖表說明我們藥品產品組合的多樣性,包括既有產品與研發管線,以及各產品所獨特鎖定的疾病。

  • We see growth opportunities with our existing products like Vizamyl for patients with suspected Alzheimer's disease as new therapies ramp up and Cerianna for metastatic breast cancer, which are used both in conjunction with PET systems for diagnosis.

    我們看到既有產品的成長機會,例如隨著新療法放量,Vizamyl 可用於疑似阿茲海默症患者;以及用於轉移性乳癌的 Cerianna;這些產品皆與 PET 系統搭配用於診斷。

  • Flurpiridaz, a pipeline product for diagnosing and assessing coronary artery disease, is expected to significantly advance PET/CT imaging. Cardiologists say it shows promise for a variety of reasons.

    Flurpiridaz 是一項用於診斷與評估冠狀動脈疾病的研發管線產品,預期將大幅推進 PET/CT 影像。心臟科醫師表示,它因多項原因而展現潛力。

  • First, it has the potential to offer more sensitivity and specificity than SPECT and Technetium, which is the standard of care. Its longer half-life may allow doses to be ordered and transported longer distances unlike other products on the market, which require on-site production which can be a limiting factor for smaller hospitals and cardiac imaging centers.

    第一,它有潛力提供比 SPECT 與 Technetium(目前的照護標準)更高的敏感度與特異性。其較長的半衰期可能使劑量得以在更長距離下訂與運送;不同於市面上其他產品需要現場製備,而這對較小型醫院與心臟影像中心可能是一項限制因素。

  • One of the most exciting advancements in molecular and functional imaging is theranostics. There's a motto for this rapidly growing field that allows you to see what you treat and treat what you see. Theranostics combines diagnostic imaging equipment, radiopharmaceuticals, both diagnostics and therapeutic, with the goal of eliminating cancer cells without affecting healthy tissues. And this has fewer side effects for patients. This approach can bring significant improvements for many cancer types and one of the reasons why molecular imaging has a very promising future.

    分子與功能性影像最令人振奮的進展之一是診療一體化(theranostics)。這個快速成長領域有句口號:看見你所治療的,治療你所看見的。診療一體化結合診斷影像設備、放射性藥物(包含診斷與治療),目標是在不影響健康組織的情況下消除癌細胞,且對病患的副作用更少。此方法可為多種癌症類型帶來顯著改善,也是分子影像擁有非常光明前景的原因之一。

  • To give you some perspective, currently, the overall theranostics market, which includes equipment, tracers and therapies, is approximately $9 billion and is expected to grow to $40 billion by 2032. Today, theranostics is primarily used in thyroid, neuroendocrine and prostate cancer. However, a growing pipeline of drugs across the industry for future applications include breast, ovarian, pancreatic and lung cancers show even more promise to potentially extend the length and quality of life for more patients. We expect to play an important role in the delivery of these new therapies.

    提供一些背景,目前整體診療一體化市場(包含設備、示蹤劑與療法)約為 90 億美元,預期到 2032 年將成長至 400 億美元。現階段,診療一體化主要用於甲狀腺癌、神經內分泌腫瘤與前列腺癌。然而,產業內針對未來應用的藥物研發管線正持續增加,涵蓋乳癌、卵巢癌、胰臟癌與肺癌,展現更大潛力,有望延長更多病患的壽命並提升生活品質。我們預期將在這些新療法的交付中扮演重要角色。

  • In the next 3 years, we plan to significantly increase our current theranostics franchise through a combination of organic and inorganic expansions. And we're excited about the opportunity to be a trusted partner, helping our customers navigate this important and growing field of medical imaging.

    在未來 3 年,我們計畫透過有機與無機擴張的組合,顯著擴大目前的診療一體化事業。我們也很期待成為值得信賴的合作夥伴,協助客戶在這個重要且成長中的醫學影像領域中前行。

  • This mission to improve outcomes across care pathways will be enabled by our announced intention to acquire MIM. After close, we plan to integrate these new capabilities into GE HealthCare's devices to enhance imaging fusion, multimodal inputs for diagnostics, therapy planning and monitoring. And by leveraging these new tools across various care areas, we can differentiate our solutions for the benefit of patients and health care systems worldwide, particularly around theranostics.

    這項改善各照護路徑結果的使命,將透過我們已宣布的收購 MIM 意向來實現。交易完成後,我們計畫將這些新能力整合至 GE HealthCare 的設備中,以強化影像融合、用於診斷的多模態輸入、治療規劃與監測。並且透過在各種照護領域運用這些新工具,我們能夠差異化我們的解決方案,造福全球病患與醫療體系,特別是在診療一體化方面。

  • In closing, we're excited about the growth potential of molecular imaging and theranostics as well as our pipeline pharmaceuticals and the collective opportunity for these innovations to enable precision care.

    最後,我們對分子影像與診療一體化的成長潛力、我們的藥品研發管線,以及這些創新共同推動精準照護的整體機會感到振奮。

  • To summarize on Slide 16, I'm extremely proud of our team's execution in 2023 and our focus on patients and customers as well as the progress we've made as a standalone company. We achieved or exceeded our financial and operational objectives we laid out at the beginning of the year. And we're making significant progress on the innovation front, including digital and artificial intelligence launches.

    在第 16 頁做個總結,我對團隊在 2023 年的執行力、對病患與客戶的專注,以及我們作為獨立公司所取得的進展感到非常自豪。我們達成或超越了年初所提出的財務與營運目標。同時,我們在創新方面也取得顯著進展,包括數位與人工智慧的產品發布。

  • We have a strong balance sheet that allows us to invest in new capabilities organically and inorganically. And we're excited about our momentum as we enter 2024. We remain on track to deliver on our medium-term targets.

    我們擁有強健的資產負債表,使我們能以有機與無機方式投資新能力。隨著邁入 2024 年,我們對目前的動能感到振奮。我們仍按計畫達成中期目標。

  • With that, I'd like to open up the call for questions.

    接下來,我想開放提問。

  • Carolynne Borders - Chief IR Officer

    Carolynne Borders - Chief IR Officer

  • Thank you, Peter. (Operator Instructions) Operator, can you please open the line?

    謝謝你,Peter。(接線員指示)接線員,請開放線路。

  • Operator

    Operator

  • (Operator Instructions) And that will come from the line of Craig Bijou with Bank of America.

    (接線員指示)接下來是美國銀行(Bank of America)的 Craig Bijou。

  • Craig William Bijou - Research Analyst

    Craig William Bijou - Research Analyst

  • So Jay, appreciate the comments on Q1. And I did want to dive a little bit deeper there. Can you guys still grow revenues in Q1, given that you do have a pretty strong year-over-year comp?

    Jay,感謝你對第一季(Q1)的說明。我確實想再深入一點。考量到你們去年同期的比較基期相當強,你們在 Q1 仍能維持營收成長嗎?

  • And then on the margin side, should we still expect margin expansion in Q1, but maybe it's at a rate a little bit lower than what you're expecting for the full year?

    另外在利潤率方面,我們是否仍應預期 Q1 會有利潤率擴張,但擴張幅度可能低於你們對全年所預期的水準?

  • James K. Saccaro - VP & CFO

    James K. Saccaro - VP & CFO

  • Craig, that's right. Overall, as I said in my prepared remarks, the first half will be lower than the second half. And the first quarter will be lower than the second quarter. And really what this comes down to is the challenging comp that we saw in Q1 of last year. I believe we had 12% revenue growth, which was really a great performance in that quarter.

    Craig,沒錯。整體而言,如同我在事先準備的發言中所說,上半年會低於下半年,而第一季會低於第二季。這主要是因為去年第一季的比較基期相當具挑戰性。我記得當時我們的營收成長約 12%,那一季的表現確實非常出色。

  • Having said that, we still expect revenue growth in the first quarter and some level of margin expansion, albeit both of those lower than the full year rates.

    即便如此,我們仍預期第一季營收會成長,且利潤率也會有一定程度的擴張,只是這兩者都會低於全年增長率。

  • Craig William Bijou - Research Analyst

    Craig William Bijou - Research Analyst

  • Got it. That's helpful. And as a follow-up, I did want to touch on China and the Anticorruption Act. And basically, I want to get your sense for what's going on there? And did you grow sales and orders in China in Q4? And how should we think about that in the early parts of '24?

    了解,這很有幫助。接著我想談談中國與反貪腐法案。基本上,我想了解你們對那邊情況的看法?你們在中國 Q4 的銷售與訂單有成長嗎?以及我們該如何看待 2024 年初的走勢?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Craig, it's Pete. Well, look, as you know, there's a lot of moving parts within China. We've talked a lot about this in the past. I think there's 3 things. I mean there is clearly a focus by the government to expand capabilities in medical coverage. And a lot of that comes down to our equipment, ultrasound CT as a first part.

    Craig,我是 Pete。你也知道,中國有很多變動因素,我們過去也談過很多。我認為有三點。第一,政府顯然聚焦擴大醫療覆蓋能力,而其中很大一部分與我們的設備有關,像是超音波與 CT 等,這是第一部分。

  • The second thing is there was a stimulus funding from last year, which was in Q4 and affected in Q1, where we did actually very, very well from a share and a growth standpoint. And then we have anticorruption. What we've seen on the ground is it's not that consistent in many different ways, meaning that certain provinces, there may be less [impact], other provinces there may be more.

    第二,去年有一筆刺激資金,在第四季到位並影響到第一季;在那段期間,我們在市占與成長方面確實表現非常、非常好。第三就是反貪腐。我們在第一線看到的情況是,它在很多方面並不一致,也就是說某些省份可能影響較小,[impact],其他省份可能影響較大。

  • I think that's going to play out in throughout the coming year. We believe overall that the approach to drive better compliance in a very large country is a good thing and that there isn't necessarily an end date as much as it's a new policy approach about how you do business. And for a company like us, it's kind of how we do business every country around the world. I think that lays it out that way.

    我認為這將會在接下來一年逐步發酵。我們整體相信,在一個非常大的國家推動更好的合規做法是件好事,而且這不一定有所謂的結束日期,與其說是一個期限,不如說是一種關於如何做生意的新政策取向。對像我們這樣的公司而言,這其實就是我們在全球各國一貫的經營方式。我想這樣就把它說清楚了。

  • That being said, last year for us in China in the first half, we had a very strong first half. We grew over 20% organic in the first half of 2023. So we're actually expecting our growth to be negative year-over-year. That's contemplated in our guidance in the first half and then in the second half, resuming to growth. And so that's kind of how we profiled it, and that's part of our 4% guidance that we've laid out.

    話雖如此,去年我們在中國上半年表現非常強勁。2023 年上半年我們的有機成長超過 20%。因此我們其實預期今年上半年同比成長會是負的。這已反映在我們對上半年的指引中,然後下半年恢復成長。所以這就是我們的輪廓描述,而這也構成了我們所提出的 4% 指引的一部分。

  • Longer term, we believe China, again, with 1.4 billion people, 400 million getting quality services today and 1 billion that need it is going to continue to be a growth market out into the future. But we've taken, I think, a prudent approach on how we take a look at no growth in the first half and then growth resuming in the second half.

    從更長期來看,我們相信中國——同樣地,擁有 14 億人口、目前有 4 億人正在獲得優質服務、還有 10 億人需要這些服務——未來仍將持續是一個成長市場。但我們採取了我認為相當審慎的做法:上半年不成長、下半年恢復成長。

  • Operator

    Operator

  • (Operator Instructions) And that will come from the line of Vijay Kumar with Evercore ISI.

    (接線員指示)接下來由 Evercore ISI 的 Vijay Kumar 提問。

  • Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team

    Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team

  • Pete, congrats on a nice (inaudible). My first, high level on the guidance here, Pete. 4% organic seems reasonable, given the tougher comps. Curious what is the guide assuming for pricing?

    Pete,恭喜你們(聽不清)。我第一個問題是關於這次指引的高層次看法,Pete。考量到比較基期更具挑戰,4% 的有機成長看起來合理。想請教這個指引對定價的假設是什麼?

  • And the book-to-bill in Q4, 1.06x, it kind of implies a capital book-for-bill was perhaps 1.08x, 1.09x. What is the relationship between -- when I look at those optical numbers of 1.08x, 1.09x capital versus revenues, right? Is there a timing element? Could perhaps 4% -- just looking at the book-to-bill, the 4% seems, it looks like it has some cushion.

    另外,第四季的接單出貨比(book-to-bill)是 1.06 倍,這似乎意味著資本設備的接單出貨比可能是 1.08 倍、1.09 倍。當我看這些表面數字——資本端 1.08 倍、1.09 倍相對於營收——兩者之間的關係是什麼?是否存在時間差因素?僅從接單出貨比來看,4% 這個數字似乎看起來有一些緩衝空間。

  • James K. Saccaro - VP & CFO

    James K. Saccaro - VP & CFO

  • So maybe I'll talk first about the sales growth for the year and then talk a little bit about pricing because I think both of those were embedded in the question. Listen, we were very pleased with the performance to close out 2023.

    我先談一下全年銷售成長,然後再談談定價,因為我想這兩點都包含在你的問題裡。聽著,我們對 2023 年收官的表現非常滿意。

  • On a full year basis, we delivered 8% at the high end of the range, in fact, a little bit in excess of our expectations for the fourth quarter. And a lot of that came down to execution in terms of translating backlog into sales, which was a testament to all the work in many of our teams.

    以全年來看,我們交出了 8% 的成績,位於區間高端,事實上第四季還略高於我們的預期。這很大一部分歸功於執行力——把在手訂單轉化為銷售——這也證明了我們許多團隊所做的努力。

  • And so as we look at 2024, we think roughly 4% is a solid number. If we think about it, we feel really good about 2023. We think the setup is solid. We think the business has proven. It's pretty durable amidst a lot of macroeconomic volatility in 2023.

    因此展望 2024 年,我們認為約 4% 是個扎實的數字。回頭看,我們對 2023 年的表現感覺很好。我們認為起手式很穩健,業務也已被驗證。在 2023 年宏觀經濟高度波動的環境下,我們的業務仍相當具韌性。

  • Our business performed pretty well. And so as a result, we did put on some incremental orders in the fourth quarter in the last couple of months of 2023, which was ahead of our expectations, so -- as I said.

    我們的業務表現相當不錯。因此,我們在 2023 年最後幾個月、第四季又新增了一些額外訂單,這超出我們的預期——就像我剛才說的。

  • And so it's early in the year. There's a lot of macro dynamics in play. Pete talked about one, but frankly, it's a volatile world that we're living in. And we set the 4% up. It's a really challenging comp, but it's set out with a very solid backlog, a solid book-to-bill ratio. And so hopefully, things cooperate and we move through the year nicely. Pete, why don't you add to that and then we can talk about price?

    現在年初,仍有很多宏觀動態在發酵。Pete 提到其中一項,但坦白說,我們所處的世界就是很動盪。我們設定 4% 的目標;比較基期確實很具挑戰,但我們有非常穩健的在手訂單、穩健的接單出貨比作為支撐。希望各種因素能配合,讓我們順利走完整年。Pete,你要不要補充一下,然後我們再談價格?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes. No, I would just -- I think you covered it, Jay, other than the fact to say that, look, we were super pleased with the order book performance. There's been obviously a reasonable amount of questions over this year about order and the translation to revenue, putting up strong orders growth in the fourth quarter, both service and equipment.

    好的。不,我只是——我想你都涵蓋到了,Jay。補充一點:我們對訂單簿的表現非常滿意。今年大家對訂單以及其轉化為營收的節奏有相當多的疑問;而我們在第四季,不論是服務還是設備,都交出了強勁的訂單成長。

  • And again, when you think about our orders book now being over $19 billion, that obviously sets us up for more gas in the tank in -- later in Q -- in the second half of 2024. But it's also a business that we have for multiyear deals that gives us visibility into '25 as well. And I think that's an important aspect here.

    再者,當你想到我們目前的訂單簿已超過 190 億美元,這顯然讓我們在 2024 年下半年——在 Q——在下半年有更多「油門」可踩。但同時,我們也有多年期合約的業務,讓我們對 2025 年也有能見度。我認為這是很重要的一點。

  • I mentioned $2.5 billion of multiyear enterprise deals, which we've been really ramping up our capability on. Not only does that help you in the current year, but it typically gives you 2 to 3 years' visibility out of business that you're going to get that you don't need to win each year.

    我提到過 25 億美元的多年期企業合約,我們一直在大幅提升這方面的能力。這不僅能幫助當年度,通常也能讓你對未來 2 到 3 年的業務有能見度,因為你不需要每年都重新去贏得同一筆生意。

  • And I think -- so for over the period of time here, I just feel very good. And again, I'm just very satisfied with the work that the team has done and the setup that we've had.

    我想——所以在這段期間裡,我的感受非常好。同樣地,我對團隊所做的工作,以及我們目前的布局與起手式,都非常滿意。

  • And to Jay's point, we tried to take into consideration all the different challenges that may be happening in the world and making sure that we've had the appropriate call to be able to deal with whatever parameters come our way.

    而且呼應 Jay 的觀點,我們試著把世界上可能發生的各種挑戰都納入考量,並確保我們做出適當的判斷,以便能應對任何可能出現的條件參數。

  • James K. Saccaro - VP & CFO

    James K. Saccaro - VP & CFO

  • Vijay, as it relates to price, like I said, we were pleased with price in '23. We delivered around 3% of price. And a lot of that comes down to a cultural focus at our company in terms of selling value and appreciation of our customers of the value that we're bringing to the table.

    Vijay,關於定價,如我所說,我們對 2023 年的定價表現很滿意。我們實現了約 3% 的價格貢獻。這很大程度來自公司文化上的聚焦:銷售價值,以及客戶對我們所帶來價值的認同與重視。

  • We are trying to innovate. You saw the R&D growth number in the quarter. We really are trying to accelerate innovation, and that translates to new and unique products. And so from our standpoint, that's unlocked a lot of our pricing opportunity.

    我們正努力創新。你也看到本季研發成長的數字。我們確實在加速創新,而這會轉化為新的、獨特的產品。因此從我們的角度來看,這解鎖了許多定價機會。

  • What we expect, consistent with the midterm plans that we've laid out, is roughly 1% to 2% pricing in 2024, and we'll continue that going forward. So I think this is about culture. It's about new products, and that's what's really -- and discipline in terms of how you construct your deals. That's really what's enabled this.

    依照我們所提出的中期計畫,我們預期 2024 年的定價大約是 1% 到 2%,並且未來也會持續。我認為這關乎文化、關乎新產品,也關乎在交易架構上的紀律。這些才是真正讓我們做到的原因。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • And I'd just support that by, again, obviously, new products aren't in the price calculation. They're in mix. But with a focus on having those come out at higher gross margins. When you have a vitality index of 26%, over 25% of your products are coming out that have a higher gross margin than the predicate ones. And ultimately, that will be the dynamic even more so than like-for-like products, which will help drive margin.

    我也想補充支持一下:當然,新產品不會算在價格(price)裡,而是算在產品組合(mix)裡。但我們的重點是讓這些新產品以更高的毛利率推出。當你的活力指數(vitality index)達到 26% 時,代表超過 25% 的產品推出時,其毛利率高於前一代產品。最終,這種動態甚至會比同品項(like-for-like)產品更能推動毛利率提升,進而帶動利潤率。

  • Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team

    Vijay Muniyappa Kumar - Senior MD and Head of Medical Supplies & Devices and Life Science Tools & Diagnostics Team

  • That's extremely helpful, Pete. And one quick follow-up here. The margin expansion guide was really impressive, 50 to 80 basis points. How much of that is coming from gross margins versus operating leverage?

    這非常有幫助,Pete。再追問一個:利潤率擴張的指引很令人印象深刻,擴張 50 到 80 個基點。這其中有多少來自毛利率提升,多少來自營運槓桿?

  • James K. Saccaro - VP & CFO

    James K. Saccaro - VP & CFO

  • Sure. And just a word on 2023 margin. We expanded 60 basis points standalone, but we did that with a dramatic increase in R&D expansion. And so that's the template that we really, really like to see.

    當然。先補充一句 2023 年的利潤率:在不含其他因素的基礎上,我們擴張了 60 個基點,但同時研發投入卻大幅增加。因此,這正是我們非常、非常希望看到的模板。

  • And so as we look at 2024, the vast majority of the expansion will come from gross margin. I used some words in my prepared remarks regarding the lean focus at the company, and that's real. What we call variable cost productivity initiatives are reshaping how we operate the manufacturing and distribution operations of the company. So that's one key element. Pricing is another key element impacting gross margin.

    展望 2024 年,擴張的絕大部分將來自毛利率。我在事先準備的發言中提到公司對精實(lean)的聚焦,那是真實存在的。我們所稱的變動成本生產力(variable cost productivity)計畫,正在重塑我們如何營運公司的製造與配送作業。這是一個關鍵要素。定價則是影響毛利率的另一個關鍵要素。

  • So in 2024, majority comes from gross margin expansion. You'll actually see R&D grow as a percentage of sales, not to the extent that it did in prior years, but it will increase as a percentage of sales as we continue to grow R&D faster. And then there will be a little bit of savings from SG&A. That's really the construct behind the 50 to 80 basis points.

    因此在 2024 年,多數來自毛利率擴張。你也會看到研發占銷售比重上升,雖然不會像前幾年那麼大幅,但隨著我們持續讓研發成長快於營收,它仍會上升。接著,SG&A 也會有一些節省。這就是 50 到 80 個基點背後的結構。

  • Operator

    Operator

  • (Operator Instructions) And that will come from the line of Matt Taylor with Jefferies.

    (接線員指示)接下來請 Jefferies 的 Matt Taylor 發問。

  • Matthew Charles Taylor - Equity Analyst

    Matthew Charles Taylor - Equity Analyst

  • So I had a follow-up. You talked a little bit about the phasing with China. And I guess I was wondering if you could comment also on other geographies and how that phase through the year, is that growth expected to be more linear in the 4% assumption?

    我有一個追問。你們稍微談到中國的時程分布。我想請問你們是否也能評論其他地區,以及這些地區在全年中的節奏如何推進?在你們假設的 4% 成長下,是否預期成長會更線性?

  • And then the other part of that question is you mentioned the customer survey that you did recently. You thought was a little bit more positive. I was wondering if you could unpack that a little bit and talk about how much that went into your forecast.

    另外,關於你提到最近做的客戶調查,你認為結果稍微更正面。我想請你再多拆解一下,談談這在多大程度上納入你們的預測。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Jay?

    Jay?

  • James K. Saccaro - VP & CFO

    James K. Saccaro - VP & CFO

  • Sure.

    當然。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • You want to take the first part and I'll take...

    你要先回答第一部分,我來回答……

  • James K. Saccaro - VP & CFO

    James K. Saccaro - VP & CFO

  • Yes, I think that -- I think China is -- listen, China is not a huge piece of our business, right? It's about 15% overall. And so the dynamic that Pete described is one that we're working through, and I think presents a nice opportunity for the second half of the year and beyond.

    是的,我認為——我認為中國——聽著,中國並不是我們業務中很大的一塊,對吧?整體大約占 15%。因此 Pete 所描述的動態是我們正在消化的,我認為這為今年下半年以及之後帶來不錯的機會。

  • As far as other geographies go, they do generally follow some of the same patterns that we -- that I described as a company overall. We're seeing -- and really, it's not about health of market or buying decision time frames, but rather it's about the comparators that we're dealing with.

    至於其他地區,它們大致也遵循我先前以公司整體所描述的一些相同模式。我們看到——其實重點不在於市場健康度或採購決策的時間框架,而是在於我們所面對的比較基期。

  • Q1, Q2, you're talking about a blended 10-ish percent revenue growth. Q3, Q4, a little bit more normal. So really, it comes down to that in terms of why the growth is going to be the way it is for us in 2024. I wouldn't point to other geographic factors other than that comp.

    第一季、第二季,你談的是約 10% 左右的混合營收成長。第三季、第四季則回到比較正常一些。所以,真正的原因在於這點,這也是為什麼我們 2024 年的成長會呈現那樣的走勢。我不會把原因歸因於其他地理因素,除了那個比較基期之外。

  • Now as it relates to the hospital capital surveys, overall, we survey each quarter. And we go to our main customers. We talk to them. We have discussions in an organized manner using the specific tool that we have in place.

    至於醫院資本支出調查,我們整體上每季都會做。我們會找主要客戶,與他們溝通,並使用我們既有的特定工具,以有組織的方式進行討論。

  • And what we said in the third quarter is we were seeing some signs of optimism from that group. And then as we did our most recent survey, I would actually point to a couple of different things. First, we did see increased buying and ordering patterns in the fourth quarter of the year. As we closed out in particular, in December, there was a buoyancy to the markets, in particular, the U.S. market that sort of supported some of the things that we saw in the survey.

    我們在第三季提到,我們從那個群體看到一些樂觀的跡象。而在最近一次調查中,我會特別指出幾個不同的面向。第一,我們確實在第四季看到採購與下單模式增加。尤其在 12 月結束時,市場呈現一種回溫的動能,特別是美國市場,某種程度上支持了我們在調查中看到的一些現象。

  • Second thing is our internal surveys continued in terms of commentary on positive expectations for growth in 2024, which I think that was a great piece of data as well.

    第二,我們的內部調查在對 2024 年成長的正面預期方面,相關評論也持續出現,我認為這也是一個很好的數據點。

  • And then third, as we looked at general external information, there were a few things that came our way. First of all, hospital profitability is robust. We saw good reports from a number of providers, a number of indices, which report on general hospital health. All of those things were good.

    第三,當我們看一些外部的整體資訊時,也有幾件事浮現。首先,醫院獲利能力相當強勁。我們從多家醫療服務提供者、以及多個反映醫院整體健康狀況的指標中看到不錯的報告,這些都很正面。

  • Second, sentiment surveys that other people conducted were also -- we use words like constructive setup into 2024. We're not sitting here saying it's going to be an unbelievable market. But we think it's going to be a solid market as we approach 2024.

    第二,其他人所做的情緒調查也——我們會用「具建設性的 2024 年布局」這類詞來形容。我們並不是坐在這裡說市場會非常驚人,但我們認為在邁向 2024 年之際,市場會是穩健的。

  • Of course, we're watching Fed rate decisions because that will have another element as people look at installing capital and making ultrasound purchases. But by and large, we feel good about how we're thinking about 2024. Pete, do you want to add anything in terms of customer discussions?

    當然,我們也在關注聯準會的利率決策,因為當人們考慮資本設備安裝與超音波採購時,這會帶來另一個影響因素。但整體而言,我們對於我們看待 2024 年的方式感覺良好。Pete,你要不要就客戶討論再補充一些?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • I think you covered it. I mean the only point, look, the balance sheets are getting better, Matt, less travelers, nursing and stuff. So their costs are going down. And so you've seen in some of the reports, profit going up, which is what we're hearing. So that's there.

    我想你都涵蓋到了。我的意思是,唯一要補充的是——你看,資產負債表正在改善,Matt,外派旅宿人員、護理等(成本)變少了,所以他們的成本在下降。因此你在一些報告中也看到獲利上升,這也正是我們聽到的。這點是存在的。

  • At the same time, demand's strong, meaning the procedures of patients coming in, either from orthopedic, cardiovascular, neuro, I mean, across the board. And so as you've heard us say as well as others, the more that those procedures grow and new innovations come out, they typically are always supported by much of the equipment that we do.

    同時,需求也很強,意思是病患進來做的處置量,不論是骨科、心血管、神經科——我是說,全面都在增加。因此如同你們聽我們以及其他人所說,這些處置越成長、越多新創新推出,通常都會由我們所提供的許多設備來支撐。

  • We talk about Alzheimer's when -- new therapies are going to come out. And as they do grow, they're going to require our equipment to image and manage safety. As new implants come out in orthopedics and move to an outpatient center, you're going to need an OECC arm to be able to do that procedure backed up with ultrasound. So that's the part that we watch is that customers' health, particularly in the United States, is improving. And the procedures' growth is on the rise.

    我們談到阿茲海默症——當新的療法推出時,隨著其成長,將需要我們的設備來進行影像檢查並管理安全性。當骨科有新的植入物推出並轉向門診中心時,你會需要一台 OECC C 臂來完成該處置,並以超音波作為支援。所以我們關注的部分是:客戶的健康狀況,特別是在美國,正在改善,而處置量的成長也在上升。

  • Operator

    Operator

  • (Operator Instructions) And that will come from the line of Larry Biegelsen with Wells Fargo.

    (接線員指示)接下來請 Wells Fargo 的 Larry Biegelsen 發問。

  • Lawrence H. Biegelsen - Senior Medical Device Equity Research Analyst

    Lawrence H. Biegelsen - Senior Medical Device Equity Research Analyst

  • I'm going to ask 2 pipeline questions. First, Pete, the slide say, you filed Flurpiridaz. You talked about it in your prepared remarks. Are you expecting approval in 2024?

    我想問兩個關於產品管線的問題。第一個,Pete,投影片上寫你們已提交 Flurpiridaz,你也在事先準備的發言中提到。你們是否預期會在 2024 年獲得核准?

  • And there are about 9 million myocardial perfusion imaging tests in the U.S. each year. Do you think Flurpiridaz can capture a significant portion of the NPI market over time? Then I have one follow-up.

    另外,美國每年大約有 900 萬次心肌灌注影像檢查。你認為 Flurpiridaz 隨著時間推進,能否在 NPI 市場中取得相當大的份額?然後我還有一個追問。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, Larry. Look, we're -- I won't give my estimate of when the agency approvals would be. But the normative rates would say at some point here in the later second half of the year based on what the normal dates would be for an NDA that we should be in the process for an approval.

    是的,Larry。你看,我不會給出我對主管機關核准時間的估計。但按常規時程來看,依 NDA 的一般審查時間點,我們應該會在今年下半年較後段的某個時點進入核准流程。

  • Look, it's a very exciting drug. And I mean you know, you've written on it as well. The standard of care forever, as I mentioned in my prepared remarks, is a SPECT camera and technetium.

    你看,這是一個非常令人振奮的藥物。而且你也知道,你也寫過相關內容。如同我在事先準備的發言中提到的,長久以來的標準照護是使用 SPECT 相機與鎝(technetium)。

  • Many of us here, I think, on the call listening in know if you go to any type of hospital (inaudible) test to see how your heart is functioning, which then directly translates into how is the plumbing? Are your vessels doing? And how is the electrical system doing? And it's a very efficient test.

    我想在這通電話上收聽的許多人都知道,如果你去任何類型的醫院做(聽不清)檢查來看你的心臟功能如何,這會直接反映到「管路」狀況如何——你的血管狀況如何——以及電傳導系統如何。這是一個非常有效率的檢查。

  • The challenge is the current products just actually don't have the level of specificity or sensitivity, meaning that they can't always point to a direct interventional action. And the early data, again, to be substantiated with the right approval is that a product like Flurpiridaz can greatly increase the specificity and sensitivity.

    挑戰在於,目前的產品其實沒有足夠的特異性或敏感度,也就是說,它們不一定能指向明確的介入性處置行動。而早期數據——當然仍需在取得適當核准後加以證實——顯示像 Flurpiridaz 這樣的產品可以大幅提升特異性與敏感度。

  • To your point, it's not a product that's used on a SPECT camera. It's a product that's used on PET/CT. PET/CT is not widely used in cardiology. If this product were to take off and capture a larger percentage of it, which we believe over time will be the case, it's going to acquire more PET/CT systems in cardiology or in cooperation with radiology. And so we're quite excited about.

    如你所說,它不是用在 SPECT 相機上的產品,而是用在 PET/CT 上的產品。PET/CT 在心臟科並未被廣泛使用。如果這個產品能夠起飛並取得更高的占比——我們相信長期來看會如此——那麼心臟科將會購置更多 PET/CT 系統,或是與放射科合作使用。因此我們對此相當興奮。

  • I think it's a great support for cardiovascular care. I know cardiologists have looked at, have been very impressed with it. But we'll see how that plays out. We're not counting on any significant ramp right now in our midterm views.

    我認為這對心血管照護是很好的支撐。我知道心臟科醫師看過後都非常印象深刻。但我們會看它如何發展。我們目前在中期觀點中,並沒有把任何顯著的快速放量納入假設。

  • We have, I'd say, a reasonable number that in some future date post approval, we'll talk about. But to your point, with the size of the opportunity, there could be some scenarios where this could end up being a larger piece of the business over time.

    我們有一個——我會說——合理的數字,未來在核准後的某個時間點我們會再談。但如你所言,考量機會的規模,確實存在一些情境,使其隨著時間推進可能成為業務中更大的一部分。

  • Lawrence H. Biegelsen - Senior Medical Device Equity Research Analyst

    Lawrence H. Biegelsen - Senior Medical Device Equity Research Analyst

  • That's very helpful. And Pete, I'd love to get an update on your progress with the Photon Counting CT technology. What are the next steps and milestones in the process to bring this to the market in the U.S. and outside the U.S.?

    這非常有幫助。Pete,我也想請你更新一下你們在 Photon Counting CT 技術上的進展。接下來的步驟與里程碑是什麼,才能把它推向美國以及美國以外的市場?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, Larry, thanks. Yes, Photon Counting, obviously, very exciting technology for CT, really probably the biggest transformation to come to CT in the last 30-some years beyond multislice. And it has that opportunity to bring better resolution, reduce dose but also bring functional capabilities within the CT world, which typically is a great anatomical imager but doesn't show what's happening more to cellular or an organ level.

    是的,Larry,謝謝。是的,Photon Counting 顯然是 CT 領域非常令人振奮的技術,可能是過去 30 多年來 CT 最大的變革(多切片之後)。它有機會帶來更好的解析度、降低劑量,同時也能在 CT 世界中帶來功能性能力;而 CT 通常是很好的解剖影像工具,但較難呈現更偏向細胞層級或器官層級正在發生的變化。

  • And photon has that capability. There's obviously some other players in the marketplace currently. We have beta sites that are actually running where we're actually doing a lot of work currently. We believe our technology approach, which is the use of a deep silicone, is unique in a lot of different ways.

    而 Photon 具備那樣的能力。顯然目前市場上也有其他參與者。我們有實際在運行的測試站點(beta sites),目前我們正在做大量工作。我們相信我們的技術路徑——也就是使用深層矽(deep silicone)——在許多不同面向上都很獨特。

  • But I would just say for the whole broader sector, all of us that are playing in it, I think this is going to be a strong revolution for the whole industry mainly because CT's ability to be installed in many different places and its just ubiquitous use for so many different diagnoses.

    但我想就整個更廣泛的產業領域來說,我們所有參與其中的人,我認為這將會是整個產業的一場強勁革命,主要因為 CT 能夠安裝在許多不同的地方,而且它在非常多不同診斷上的使用幾乎無所不在。

  • So stand by. More to come. We'll be talking more about it throughout the year, but we're making good progress on the platform. So thanks for the question.

    所以請拭目以待,後續還會有更多消息。我們會在今年持續更多談到它,但我們在這個平台上正取得良好進展。謝謝你的提問。

  • Operator

    Operator

  • (Operator Instructions) And that will come from the line of Joanne Wuensch with Citi.

    (接線員指示)接下來是 Citi 的 Joanne Wuensch。

  • Joanne Karen Wuensch - MD

    Joanne Karen Wuensch - MD

  • As you move more and more into AI-enabled technologies, could you comment on your thoughts on how to translate that to dollars and cents? Is it a subscription model? Is it Software-as-a-Service? How do we think about that?

    隨著你們越來越多地投入 AI 賦能技術,你能否談談你們如何把它轉化為實際的金額(dollars and cents)?會是訂閱模式嗎?會是軟體即服務(SaaS)嗎?我們該如何思考?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, Joanne, it's a great question. And I would say our strategies are evolving. And it will be, in many ways, multifacet.

    是的,Joanne,這是個很好的問題。我會說我們的策略正在演進,而且在很多方面會是多面向的。

  • So just to give an example, in today's world, where we have a product like AIR Recon DL, which again is this new way of actually how an MRI actually creates an imaging using artificial intelligence and the corresponding upgrades that we can take to our installed base, today, those fundamentally result in a higher price value proposition, higher gross margins for an acquisition in that space.

    舉例來說,在今天的世界裡,我們有像 AIR Recon DL 這樣的產品——這同樣是一種全新的方式,讓 MRI 透過人工智慧來生成影像,以及我們能對既有裝機基礎(installed base)進行的相應升級——目前這些基本上會帶來更高的定價價值主張,並在該領域的設備銷售中帶來更高的毛利率。

  • And I think there's still going to be plenty of those opportunities to say this product by itself and this product plus AI is actually 4, 5, 10 points higher in gross margin because of what it actually does. And that will still account for a reasonable part of our growth.

    我認為仍然會有很多這類機會:也就是單獨這個產品,與「這個產品加上 AI」相比,毛利率可能高出 4、5 甚至 10 個百分點,因為它實際能做到的事情不同。而這仍將占我們成長的相當一部分。

  • The second part then is actually bringing certain capabilities via a SaaS model as their pure standalone software capability. So take -- in my prepared remarks, I talked about the App Orchestrator.

    第二部分則是透過 SaaS 模式,把某些能力以純粹獨立的軟體能力提供。比如——在我事先準備的發言中,我提到了 App Orchestrator。

  • There's a great example of a product that will be cloud-based, can fit on many different [pack] systems and work with multi-vendor equipment. And customers may decide that at one hospital or their whole network, they want it. And so they could pay for one on-site capability to be a SaaS, they could pay for multiple.

    那就是一個很好的例子:它會是雲端化的,可以適配許多不同的系統,並可與多家供應商(multi-vendor)的設備協同運作。客戶可能會決定在某一家醫院或其整個醫療網路都要使用。因此他們可以為一個院內能力以 SaaS 方式付費,也可以為多個點位付費。

  • And then riding upon that will be applications from other third parties. And we will have an opportunity to say you'll get 70%, we'll take 30% as an enabler into our broader installed base in others. And so there's a multifaceted way.

    而在此之上,還會有來自其他第三方的應用。我們將有機會採取分潤:你們拿 70%,我們作為使能者拿 30%,把它帶入我們更廣泛的裝機基礎以及其他場景。因此這是一種多面向的方式。

  • I would say in 2024, one of our big operating priorities or big priorities we have is really building out this go-to-market and monetization model. But it's going to evolve everything from more value to a piece of hardware, which we can actually attain more value for all the way through different -- almost down to buy the use capabilities. That -- again, that's going to expand over multiple years, but that's how we're thinking about it and putting in place the right type of SaaS backbone for the whole company.

    我會說在 2024 年,我們的一個重要營運優先事項(或重大優先事項)就是把這套市場進入(go-to-market)與變現(monetization)模式真正建立起來。但它會持續演進:從讓硬體本身更具價值、使我們能取得更多價值,一直到不同的——幾乎是按使用能力購買(buy-the-use capabilities)的模式。這——同樣地——會在多年期間逐步擴展,但這就是我們的思考方式,也是在為全公司建立正確類型的 SaaS 底座(backbone)。

  • Operator

    Operator

  • (Operator Instructions) And that will come from the line of Graham Doyle with UBS.

    (接線員指示)接下來是 UBS 的 Graham Doyle。

  • Graham Doyle - Analyst

    Graham Doyle - Analyst

  • Can we just touch on China again, just to clarify one of the statements earlier? You said you're expecting no growth but also negative growth in the first half. And just is it negative or no growth, i.e., flat?

    我們能再談一下中國嗎,想釐清你先前的一句話?你說你預期沒有成長,但上半年也會是負成長。那到底是負成長還是沒有成長,也就是持平?

  • And just for the full year, are you expecting China to grow? And then just a quick clarification one after that on the order book.

    另外就全年而言,你們預期中國會成長嗎?然後再快速釐清一下訂單簿(order book)的問題。

  • James K. Saccaro - VP & CFO

    James K. Saccaro - VP & CFO

  • Sure. On China, we expect a decline in the first half. But remember, in Q1 of 2023 and Q2 of 2023, we had around 20% growth. So we've always kind of modeled the decline in the first half, growth in the second half. And as a result, we're expecting growth for the year.

    好的。關於中國,我們預期上半年會下滑。但請記得,在 2023 年第一季與第二季,我們大約有 20% 的成長。所以我們一直以來的模型大致是:上半年下滑、下半年成長。因此,我們預期全年仍會成長。

  • Graham Doyle - Analyst

    Graham Doyle - Analyst

  • Perfect. That's super clear. And then just on the orders, I think you mentioned quite a sizable multiyear contract win. Does that get all booked in the Q4 '23 as well then?

    很好,這非常清楚。那再問訂單方面,我想你提到了一個相當可觀的多年期合約得標。那這也會在 2023 年第四季全部入帳(booked)嗎?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, Graham. What I actually, I think, referenced was over the year, multiple enterprise deals that we won that amount to over $2.5 billion. Our current process is as we bring in significant amounts of orders, we typically don't book out beyond a 2-year window of our orders.

    是的,Graham。我實際上提到的,我想,是我們在全年贏得的多筆企業級(enterprise)交易,合計超過 25 億美元。我們目前的流程是:當我們取得大量重要訂單時,通常不會把訂單簿入帳範圍延伸到超過 2 年的期間。

  • So we have something that's captured for 5, 6, 10 years. We aren't actually booking years 7 -- excuse me, 3 and beyond in our current order book. That's not our approach that we implement. So the orders we put in the 3% growth are very near-term orders that we won in the fourth quarter that will see play out in '24 and '25.

    所以即使我們有一些合約涵蓋 5、6、10 年,我們在目前的訂單簿中其實不會把第 7 年——抱歉,是第 3 年及以後——入帳。這不是我們採行的方法。因此,我們在 3% 成長中所納入的訂單,都是我們在第四季贏得、非常近端的訂單,將在 2024 與 2025 年逐步反映。

  • Graham Doyle - Analyst

    Graham Doyle - Analyst

  • Perfect. And really cheeky quick one. On that Photon Counting you brought up earlier, is it your expectation that on -- I don't know, like call it, a 5-year view, this becomes kind of the standard of care within CT more broadly as it becomes economic, and we should expect that this -- most CTs in Europe and certainly the U.S. become Photon Counting?

    很好。再問一個有點冒昧的快問:你先前提到的 Photon Counting,你是否預期——我不知道,比如以 5 年的視角——當它變得更具經濟性時,會在更廣泛的 CT 領域成為某種標準照護(standard of care)?我們是否應該預期歐洲、當然還有美國的大多數 CT 都會變成 Photon Counting?

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • I think 5 years is a little bit optimistic. I mean I think I've heard what others have said as well. I think in the 10-year window, that's probably more realistic.

    我認為 5 年有點樂觀。我是說,我也聽過其他人怎麼說。我覺得在 10 年的時間窗內,可能更現實。

  • Keep in mind, 85% of all CTs in the world tend to be more mid-tier value-based products. Some of them sell for $200,000, $300,000 in different parts of the world. So it's a wide community of what's in a CT. To your point is on the premium end and stuff, I think in the 5-year window, yes, you're going to see a significant higher percentage of Photon Counting.

    請記住,全球 85% 的 CT 往往是較中階、以價值為導向的產品。在世界不同地區,有些售價是 20 萬、30 萬美元。所以 CT 的產品光譜非常廣。就你提到的高端市場等,我認為在 5 年的時間窗內,是的,你會看到 Photon Counting 的占比顯著提高。

  • Operator

    Operator

  • (Operator Instructions) And that will come from the line of Anthony Petrone with Mizuho.

    (接線員指示)接下來是 Mizuho 的 Anthony Petrone。

  • Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst

    Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst

  • Congrats on a solid year, your post-spin. Maybe I'll start, Pete, with just a question on theranostics. You have it in the slide deck here. Obviously, GE HealthCare, well positioned on the diagnostics side. You mentioned growth organically and inorganically. Just wondering how you're thinking about the other pieces of theranostics.

    恭喜你們在分拆後交出穩健的一年。也許我先從 theranostics(診療一體化)開始,Pete,問一個問題。你們在投影片裡有提到。顯然 GE HealthCare 在診斷端的布局很到位。你提到有機與無機成長。想請教你如何看待 theranostics 的其他組成部分。

  • You have therapeutics and supply chain. You can grow more in diagnostics. So just maybe your thoughts on how that space is consolidating and where GE can play specifically? And I'll have a follow-up for Jay on capital allocation.

    你們有治療端與供應鏈。你們可以在診斷端成長更多。所以想聽聽你對這個領域整併趨勢的看法,以及 GE 具體可以在哪些方面參與?另外我會再追問 Jay 一個關於資本配置(capital allocation)的问题。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes. No, it's a good question. I mean, obviously, at the baseline level, as these therapies take off, PET/CT's a critical product. I mean for all practical purposes, it's a limited world of folks that manufacture a PET/CT and PET/MR. We're one of them.

    是的。不,這是個好問題。我的意思是,很明顯在最基本層面,隨著這些療法起飛,PET/CT 是一個關鍵產品。就實務而言,能製造 PET/CT 與 PET/MR 的廠商其實不多,我們是其中之一。

  • We think to do this effectively, you have to have a multi-head SPECT/CT. We have a 12-head system called the StarGuide. None of our major competitors really have that product.

    我們認為要有效做到這件事,你必須擁有多探頭(multi-head)的 SPECT/CT。我們有一套 12 探頭系統,名為 StarGuide。我們的主要競爭對手基本上沒有這樣的產品。

  • Why is that important? If you have a traditional 2-head, it's an hour to do the study versus you can do it in 15 minutes or less. You can't run an effective theranostics department if you don't have a multi-head camera. So that's kind of the stakes.

    為什麼這很重要?如果你用傳統的 2 探頭,做一次檢查要一個小時;但用它你可以在 15 分鐘或更短完成。如果沒有多探頭相機,你不可能有效運作一個診療一體化(theranostics)部門。這就是基本門檻。

  • The next thing is you need to integrate those images and look at them together to diagnose, look at radiation dose. Patient might have had external beam radiation. They get radiation from the drug itself. You need to look at both of those.

    下一件事是,你需要把那些影像整合起來並一起檢視,用於診斷、評估輻射劑量。病人可能接受過體外放射治療(external beam radiation),也會從藥物本身獲得輻射。你需要同時看這兩者。

  • MIM Software is really the best in the world. They're going to be part of us post close. That's going to bring a missing link. It's also a capability that really nobody else in the industry has when you couple that with those products.

    MIM Software 真的可以說是全球最好的。他們在交易完成後將成為我們的一部分。這會補上缺失的一環。當你把這項能力與那些產品結合時,這也是業界幾乎沒有人具備的能力。

  • And then on the tracer side, we're the only company who has the equipment and manufacturers, tracers. Others distribute, but there's a big difference between just shipping it around and making it. And so we have the logistics capability. We also have the manufacturing capability. And we also make the cyclotrons, which, again, are particle accelerators that actually help create many of these.

    接著在示蹤劑(tracer)這一端,我們是唯一一家同時擁有設備與製造能力、能夠生產示蹤劑的公司。其他人是做分銷,但單純把產品運來運去,和真正把它製造出來,差別很大。因此我們具備物流能力,也具備製造能力。我們也製造迴旋加速器(cyclotrons),同樣地,那是粒子加速器,實際上有助於生成其中許多產品。

  • So there's multiple opportunities here either working with some of the pharmaceutical companies directly, playing a leadership role with customers on how you deliver these doses. And just to remind everybody, unlike other drugs where you can just deliver in any center, these products have a half-life, which means the moment you make them, they're degrading.

    所以這裡有多種機會:可以直接與一些製藥公司合作,在如何向客戶交付這些劑量方面扮演領導角色。也提醒大家,與其他藥物不同的是,這些產品有半衰期,這表示你一旦製造出來,它們就開始衰減。

  • And so how you actually take an order and get it to a patient that day for the right potency is one of the things we have expertise in. So again, as these grow and what we're excited about is the impact they're going to have on patients, effectiveness and low side effects. We've got most of the capabilities to play different roles throughout the growth of this, and that's what we're planning to do.

    因此,如何實際接單並在當天以正確效價送達病患,是我們具備專業能力的領域之一。所以再次強調,隨著這些業務成長,以及我們所期待它們對病患帶來的影響——更高的療效與更低的副作用——我們擁有在其成長過程中扮演不同角色所需的大多數能力,而這正是我們計畫要做的。

  • Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst

    Anthony Charles Petrone - MD & Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst

  • Helpful. And Jay, real quick on capital allocation, uses of cash for this year. Is M&A more of the priority? You did $1 billion debt pay down. And then just free cash flow conversion, that would be helpful.

    很有幫助。Jay,快速問一下今年的資本配置、現金用途。併購(M&A)是否更優先?你們做了10億美元的債務償還。另外,自由現金流轉換率方面也請說明一下,會很有幫助。

  • James K. Saccaro - VP & CFO

    James K. Saccaro - VP & CFO

  • Sure. Thanks for the question. I think 2023 was really a great case study in terms of how we think about capital allocation. It starts, to your point, with free cash flow. We were able to deliver 95% conversion, which we were very proud of.

    當然。謝謝你的問題。我認為2023年在我們如何看待資本配置方面,確實是一個很好的案例研究。正如你所說,起點是自由現金流。我們達成了95%的轉換率,對此我們非常自豪。

  • We did a lot of work on the balance sheet on working capital balances and collections on inventory turns, which I commented on in my prepared remarks. And the result was we exceeded our cash flow expectations by a good margin. And we set up 2024 with another solid 90% conversion rate and free cash flow growth.

    我們在資產負債表方面做了很多工作,包括營運資金餘額與收款、庫存周轉等,我在事先準備的發言中也提到過。結果是,我們的現金流表現大幅超出預期。我們也為2024年奠定基礎,設定另一個穩健的90%轉換率以及自由現金流成長。

  • And so then the question is, how do you deploy that? Well, in 2023, the first thing we like to do is reinvest in the business to accelerate growth. And so what we were able to do is drive EBIT expansion of 60 basis points despite 20-ish percent growth in R&D. And we also significantly expanded CapEx investments. So point one, reinvest in the business.

    接著問題就是:要如何運用這些現金?在2023年,我們首先喜歡做的是再投資於業務,以加速成長。因此,我們在研發(R&D)成長約20%的情況下,仍推動了EBIT擴張60個基點。我們也大幅增加了資本支出(CapEx)投資。所以第一點:再投資於業務。

  • The second thing we like to do is strategic M&A. Over the course of 2023, we announced 3 deals, IMACTIS, Caption and MIM. All of them have the profile of deals that we like: strategically relevant, accretive to our business, really solid ROIs over time. And so all of them hit the profile and made us a bit more competitive in the marketplace with more offerings for our customers.

    第二點我們喜歡做的是策略性併購(M&A)。在2023年期間,我們宣布了3筆交易:IMACTIS、Caption和MIM。它們都符合我們偏好的交易特徵:具策略相關性、對我們業務具增益(accretive)、長期而言有非常扎實的投資報酬率(ROI)。因此,這些交易都符合我們的標準,也讓我們在市場上更具競爭力,能為客戶提供更多產品與服務。

  • Also in 2023, we made a number of minority investments that allow us to learn about new areas in a sort of experimental manner. So we don't talk too much about all investments, but we make quite a few in 2023. And over time, we expect these to yield dividends.

    同樣在2023年,我們也進行了多項少數股權投資,讓我們能以某種實驗性的方式去了解新領域。我們不會對所有投資談太多,但2023年我們確實做了不少。隨著時間推進,我們預期這些投資將帶來回報。

  • We also like to focus on the balance sheet. So we paid down $1 billion in debt in 2023, significantly enhancing the financial flexibility going forward. And finally, we paid a dividend.

    我們也重視資產負債表。因此我們在2023年償還了10億美元的債務,顯著提升了未來的財務彈性。最後,我們也發放了股利。

  • So I guess the way I think about it, everything was on display in 2023 in terms of how we think about a disciplined capital allocation strategy. And as we move forward, I would expect to see more of the same. All of that, though, as I said at the beginning of this was -- is unlocked by cash flow generation, which is a real area of focus for us.

    所以我想說的是,2023年充分展現了我們如何看待一套有紀律的資本配置策略。展望未來,我預期會看到更多相同的做法。不過,正如我一開始所說,這一切都建立在現金流的產生能力之上,而這也是我們高度聚焦的重點領域。

  • Operator

    Operator

  • We do have time for one final question, and that will come from the line of Patrick Wood with Morgan Stanley.

    我們還有時間再回答最後一個問題,將由摩根士丹利(Morgan Stanley)的Patrick Wood提問。

  • Patrick Wood

    Patrick Wood

  • I'll keep it to one, just given the timing. I'll make it a short one. Thank you for the detail on the pricing side. Just kind of curious like how that's flowing through on the service book.

    考量時間我只問一題,我會簡短一點。謝謝你們在定價方面的細節。我有點好奇,這在服務訂單簿(service book)上是如何反映的。

  • Obviously, you get the 1-year warranty, but where you're re-signing service agreements, are you seeing a similar kind of price uplift to what you're getting on the hardware side so that, that traditional ratio between the 2 is remaining relatively constant? Just curious what you're seeing there.

    顯然你們提供1年保固,但在你們重新簽訂服務合約時,你們是否也看到與硬體端類似的價格上調,使得兩者之間傳統的比例大致維持相對穩定?只是想了解你們那邊看到的情況。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Yes, Patrick, we've benefited from multiyear contracts, we have been able to actually have escalators on not only just on upfront, but then actually have escalators through the years. And then also, we have parts, significant large parts business as well as time and material.

    是的,Patrick,我們受益於多年期合約;我們不僅能在前期價格上設定調整機制(escalators),也能在後續年度持續有調整機制。此外,我們也有零件業務——規模相當可觀——以及按工時與材料計費(time and material)的業務。

  • And then the other aspect of it is different services that we offer. It might be asset tracking tools, things of that nature. But I would say we've had the good fortune across the board to be able to get some price across all those different vehicles in service.

    另外一個面向是我們提供的不同服務,可能是資產追蹤工具之類的。但我會說,我們很幸運在各方面都能在服務的各種不同載體上取得一定程度的價格提升。

  • I would say the other thing, and it's kind of a given point, but it's important to note that when services are really one of our highest margin offerings that we have. When you are gaining share, as I mentioned earlier on the call, ultimately, to your point, when you get to month 13, that becomes a service contract. And that higher mix of service over time also is an important driver of our future business. Thanks for that question.

    我想另外一點——這有點是既定事實,但仍很重要——要注意的是,服務是我們毛利率最高的產品/服務之一。當你在市占上有所提升時,正如我先前在電話會議中提到的,最終如你所說,到了第13個月,那就會轉為服務合約。而隨著時間推進,服務占比提高也會成為我們未來業務的重要驅動因素。謝謝你的問題。

  • Operator

    Operator

  • And Mr. Arduini, I'll turn the call back over to you for any closing remarks.

    Arduini先生,我把電話會議交回給您,請您做任何結語。

  • Peter J. Arduini - President, CEO & Director

    Peter J. Arduini - President, CEO & Director

  • Thank you. Thank you. Look, I'd just like to close by saying thank you so much to our colleagues here at GE HealthCare. It's been a great year. There's been a lot of great work and tireless efforts to go into the first year as a public company.

    謝謝。謝謝。各位,我最後想說的是,非常感謝我們GE HealthCare的同仁。這是一個很棒的一年。作為一家上市公司的第一年,大家投入了大量出色的工作與不懈的努力。

  • But importantly, with all of that, the focus on our patients and customers to deliver safe, high-quality products that make a difference. It's at the core of our lean mindset is customers first.

    但更重要的是,在這一切之中,我們始終聚焦於病患與客戶,提供安全、高品質、能帶來改變的產品。這也是我們精實思維(lean mindset)的核心:客戶第一。

  • We delivered on all of our commitments that we set to deliver in 2023 and as Jay and as we spoke about, really sets us up well for 2024. Investments we made in R&D are coming out. We have a full pipeline of new products and new clinical indications.

    我們達成了2023年所設定的所有承諾;正如Jay以及我們所談到的,這也讓我們為2024年做好了充分準備。我們在研發(R&D)上的投資正在開花結果。我們擁有完整的新產品與新臨床適應症管線。

  • With that, I'd just like to say thank you for joining the call today. And we look forward to connecting with you at one of our upcoming conferences. Thank you so much.

    最後,我想感謝各位今天參與本次電話會議。我們也期待在即將到來的某場會議上與各位交流。非常感謝。

  • Operator

    Operator

  • This concludes today's program. Thank you all for participating. You may now disconnect.

    今天的節目到此結束。感謝各位參與。您現在可以掛線。